Fourth-quarter device financing reached $4.2bn, up from the previous quarter’s $3.3bn. The initial public offering category made up the most, accounting for $1.3bn, or 32%, of the Q4 total, followed by debt, which brought in an aggregate $1bn, or 25% of the Q4 financing dollars (see Exhibit 1).
Financing: 2020 Ends On A High Note For Medtech
A look at financing activity across the medical device and in vitro diagnostics industries, October-December 2020
During Q4, device company fundraising totaled $4.2bn; while in vitro diagnostic firms and research tools players raised $6.1bn.
More from Business
More from Medtech Insight
• By
Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.
• By
MedTech Europe is ready to become involved and shape Europe’s Life Sciences Strategy and help drive regulatory simplification from the top to make the EU “the world’s most attractive place for life sciences by 2030.”
• By
The UK government’s blueprint to deliver an NHS "fit for the future" was released on July 3.